抗凝治疗对血管腔内动脉瘤修复术后结局影响的系统评价与Meta分析
该系统评价与Meta分析纳入16项研究共35739例患者,比较接受抗凝治疗与未接受抗凝治疗患者行血管腔内动脉瘤修复术(EVAR)后的结局。抗凝患者死亡(HR=1.93,95%CI=1.03-3.63)、内漏(HR=2.13,95%CI=1.55-2.93)、再干预(HR=1.79,95%CI=1.27-2.52)及瘤囊扩张(HR=2.72,95%CI=1.57-4.72)的风险均显著高于未抗凝患者。作者认为抗凝是标准EVAR术后的不良预后因素,应在决策、知情同意和监测策略中加以考虑。
要点
- 抗凝患者EVAR术后死亡风险显著高于未抗凝者(HR=1.93,95%CI=1.03-3.63)。
- 抗凝患者内漏(HR=2.13)、再干预(HR=1.79)及瘤囊扩张(HR=2.72)风险均显著升高。
- 作者认为抗凝是EVAR术后不良预后因素,应纳入决策、知情同意与监测策略。
核心结论
- 抗凝是标准EVAR术后的不良预后因素,应在决策、知情同意和监测策略中加以考虑。
- 抗凝患者EVAR术后死亡、内漏、再干预及瘤囊扩张风险均显著高于未抗凝患者。
- 抗凝患者需被告知EVAR失败率较高,该人群可能需要加强监测策略。
研究设计与样本
- 系统评价与Meta分析,遵循PRISMA指南并注册方案(CRD42022375894)。
- 检索Ovid界面下MEDLINE、EMBASE和CENTRAL数据库,截至2022年11月。
- 纳入16项比较抗凝与未抗凝患者EVAR结局的研究,共35739例个体。
- 采用纽卡斯尔-渥太华量表(NOS,最高9分)评估研究质量,并采用GRADE框架评价证据。
- 时间-事件Meta分析采用逆方差法和随机效应模型计算风险比(HR)及95%置信区间(CI)。
主要发现
- 抗凝患者死亡风险显著高于未抗凝患者(HR=1.93,95%CI=1.03-3.63)。
- 抗凝患者内漏风险显著高于未抗凝患者(HR=2.13,95%CI=1.55-2.93)。
- 抗凝患者再干预风险显著高于未抗凝患者(HR=1.79,95%CI=1.27-2.52)。
- 抗凝患者瘤囊扩张风险显著高于未抗凝患者(HR=2.72,95%CI=1.57-4.72)。
- NOS评分中位数为7分(范围4-9分);死亡和再干预的证据确定性为极低,内漏和瘤囊扩张为低。
关键数值与推荐
- 纳入标准为比较抗凝与未抗凝患者EVAR结局的研究。
- NOS评分中位数为7分(范围4-9分)。
- 死亡和再干预的证据确定性为极低,内漏和瘤囊扩张为低。
临床怎么用
- 作者认为抗凝是标准EVAR术后的不良预后因素,应在决策、知情同意和监测策略中加以考虑。
- 作者认为抗凝患者需被告知EVAR失败率较高,该人群可能需要加强监测策略。
局限性
- 死亡和再干预的证据确定性为极低,内漏和瘤囊扩张的证据确定性为低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Our objective was to investigate whether patients who receive anticoagulation therapy have different outcomes after endovascular aneurysm repair (EVAR) from those who do not. MATERIALS AND METHODS: We conducted a systematic review of studies that compared outcomes of EVAR in patients who were on therapeutic anticoagulation vs those who were not. We developed and reported the review in accordance with the PRISMA guidelines with a registered protocol (CRD42022375894). The Ovid interface was used to search Medical Literature Analysis and Retrieval System Online (MEDLINE), Excerpta Medica Database (EMBASE), and Cochrane Central Register of Controlled Trials (CENTRAL) up to November 2022. The quality of studies was assessed with the Newcastle-Ottawa Scale (NOS) (maximum score=9), and the evidence was appraised with the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework. The hazard ratio (HR) and 95% confidence interval (CI) was the effect estimate in time-to-event meta-analyses, calculated using the inverse-variance statistical method and random-effects models. RESULTS: Sixteen studies qualified for inclusion reporting a total of 35 739 individuals. Anticoagulated patients had a statistically significantly higher hazard of death (HR=1.93, 95% CI=1.03-3.63), endoleak (HR=2.13, 95% CI=1.55-2.93), reintervention (HR=1.79, 95% CI=1.27-2.52), and aneurysm sac expansion (HR=2.72, 95% CI=1.57-4.72) than patients not receiving anticoagulation therapy. The median score on the NOS was 7 (range=4-9). The certainty of evidence was very low for mortality and reintervention and low for endoleak and sac expansion. CONCLUSIONS: Anticoagulation is a poor prognostic factor after standard EVAR and should be considered in decision-making, consent processes, and surveillance strategies.Clinical ImpactThe number of individuals who take anticoagulation treatment has been rapidly increasing over the recent years. We aimed to investigate the effect of such treatment on outcomes after endovascular aneurysm repair (EVAR). Anticoagulated patients were found to have increased mortality, endoleak, and reintervention rates after EVAR compared to their non-anticoagulated counterparts. Anticoagulation therapy has a prognostic role in EVAR and should be considered in decision making and EVAR surveillance. Anticoagulated patients need to be informed of the higher failure rates of EVAR, and intensified surveillance strategies may need to be implemented in this patient cohort.
引用
- Kontopodis N, Galanakis N, Ioannou CV, et al. Systematic Review and Meta-Analysis of the Effect of Anticoagulation on Outcomes After Endovascular Aneurysm Repair. J Endovasc Ther. 2023. PMID: 38031419. doi:10.1177/15266028231214761
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。